All News

ASC30, an investigational glucagon-like 1-peptide receptor agonist, demonstrates mean weight reductions from baseline of 4.3% and 6.3% for 2 separate cohorts.

A PDUFA target action date for the PrEP therapy has been set for June 19, 2025.

Patients with musculoskeletal pain were treated with cryotherapy spray to assess its use in providing immediate and sustained pain relief.

How pharmacies will pay for the Medicare Drug Price Negotiation Program

The FDA initially approved deucravacitinib (Sotyktu) in September 2022 to treat moderate-to-severe plaque psoriasis.

Explore key legislative actions changing pharmacy practice in 2025 and beyond.

Patients prescribed high-dose opioids were given the option to switch to buprenorphine in hopes of improving pain and reducing opioid dosage.

Previously, dupilumab (Dupixent) received orphan drug designation for bullous pemphigoid.

The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access to drugs that the organization had reviewed for cost effectiveness in 2022.

Researchers investigate the effects of subanesthetic doses of esketamine for the treatment of pain and cognition in patients undergoing surgery.

The vaccine is the first virus-like particle single-dose vaccine for chikungunya for patients 12 years and older.

Among a diverse cohort of patients with type 2 diabetes (T2D), researchers examined the use of automated insulin delivery for lowering hemoglobin A1c levels.

Denosumab-dssb is approved as a 60 mg pre-filled syringe as a biosimilar for Prolia and 120 mg vial as a biosimilar for Xgeva.

The combination includes 2 previously approved vaccines to target the 5 major serogroups of Neisseria meningitidis.

In order to meet national targets, the United States should expand vaccination administration in complementary sites like pharmacies.

Currently, blood-thinning medications are only prescribed to patients who have already had a heart attack or stroke, as the drugs can cause serious bleeding.

The drug is the first rapid-acting insulin biosimilar product approved for use by the FDA, marking a significant milestone in diabetes treatment.

Identifying women who are at risk for postpartum depression sooner can lead to quicker and possibly preventative treatment.

Among providers who took part in a recent study, 57% reported increased vaccination rates after implementing a quality improvement initiative.

Investigators note there were no safety signals related to the vaccine candidate, and participants who developed E. coli disease received treatment and care.

What are some key strategies for keeping your pharmacy thriving in 2025?

A dose response is observed with the highest dose of the drug and mitigating withdrawal symptoms for patients with cannabis use disorder.

Pharmacy industry experts gathered for a webinar detailing the upcoming trends expected to take shape in 2025.

More detailed information can be found on the CDC’s website at www.cdc.gov/vaccines.

For weight loss and antihypertensive effects on systolic and diastolic blood pressure, semaglutide also had increased effects.

Erin Fox, PharmD, MHA, BCPS, FASHP, joined Drug Topics to discuss ultra-high-cost drugs and the American Society of Health-System Pharmacists 2025 Pharmacy Forecast.

A discussion on the new nonopioid selective NaV1.8 pain signal inhibitor with Madison Irwin, PharmD, BCPS.

For patients with atopic dermatitis reporting moderate-to-severe scratching, researchers explored the efficacy of an AI-enabled wearable sensor with closed-loop haptic feedback.

Multiple micronutrient supplements showed the greatest impact on reducing the risk of giving birth to small vulnerable newborns.

The tablet formation of risdiplam (Evrysdi) demonstrates bioequivalence to the oral formulation of the drug.